Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone.

Engellau J, Seeger L, Grimer R, Henshaw R, Gelderblom H, Choy E, Chawla S, Reichardt P, O'Neal M, Feng A, Jacobs I, Roberts ZJ, Braun A, Bach BA.

World J Surg Oncol. 2018 Sep 19;16(1):191. doi: 10.1186/s12957-018-1478-3.

2.

Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study.

Udar N, Lofton-Day C, Dong J, Vavrek D, Jung AS, Meier K, Iyer A, Slaughter R, Gutekunst K, Bach BA, Peeters M, Douillard JY.

J Cancer Res Clin Oncol. 2018 Oct;144(10):2001-2010. doi: 10.1007/s00432-018-2688-3. Epub 2018 Jul 17.

3.

Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer.

Kim TW, Peeters M, Thomas A, Gibbs P, Hool K, Zhang J, Ang AL, Bach BA, Price T.

Clin Cancer Res. 2018 Nov 15;24(22):5602-5609. doi: 10.1158/1078-0432.CCR-17-3377. Epub 2018 Jun 13.

PMID:
29898991
4.

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.

Siena S, Sartore-Bianchi A, Garcia-Carbonero R, Karthaus M, Smith D, Tabernero J, Van Cutsem E, Guan X, Boedigheimer M, Ang A, Twomey B, Bach BA, Jung AS, Bardelli A.

Ann Oncol. 2018 Jan 1;29(1):119-126. doi: 10.1093/annonc/mdx504.

5.

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.

Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, Hall M, Renard V, Pignata S, Kristeleit R, Altintas S, Rustin G, Wenham RM, Mirza MR, Fong PC, Oza A, Monk BJ, Ma H, Vogl FD, Bach BA.

Eur J Cancer. 2017 Jan;70:111-121. doi: 10.1016/j.ejca.2016.09.004. Epub 2016 Dec 1.

PMID:
27914241
6.

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.

Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma H, Vogl FD, Bach BA, Oza AM.

Gynecol Oncol. 2016 Oct;143(1):27-34. doi: 10.1016/j.ygyno.2016.07.112. Epub 2016 Aug 18.

PMID:
27546885
7.

Population-based study of giant cell tumor of bone in Sweden (1983-2011).

Amelio JM, Rockberg J, Hernandez RK, Sobocki P, Stryker S, Bach BA, Engellau J, Liede A.

Cancer Epidemiol. 2016 Jun;42:82-9. doi: 10.1016/j.canep.2016.03.014. Epub 2016 Apr 6.

PMID:
27060625
8.

Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1).

Fujiwara K, Monk BJ, Lhommé C, Coleman RL, Brize A, Oaknin A, Ray-Coquard I, Fabbro M, Provencher D, Bamias A, Vergote I, DeCensi A, Zhang K, Vogl FD, Bach BA, Raspagliesi F.

Ann Oncol. 2016 Jun;27(6):1006-13. doi: 10.1093/annonc/mdw147. Epub 2016 Mar 30.

PMID:
27029706
9.

Incidence Trends in the Diagnosis of Giant Cell Tumor of Bone in Sweden Since 1958.

Rockberg J, Bach BA, Amelio J, Hernandez RK, Sobocki P, Engellau J, Bauer HC, Liede A.

J Bone Joint Surg Am. 2015 Nov 4;97(21):1756-66. doi: 10.2106/JBJS.O.00156.

PMID:
26537163
10.

Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.

Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, Vaz G, Wunder JS, Seeger LL, Feng A, Roberts ZJ, Bach BA.

Ann Surg Oncol. 2015 Sep;22(9):2860-8. doi: 10.1245/s10434-015-4634-9. Epub 2015 Jun 2.

11.

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.

Fuchs CS, Azevedo S, Okusaka T, Van Laethem JL, Lipton LR, Riess H, Szczylik C, Moore MJ, Peeters M, Bodoky G, Ikeda M, Melichar B, Nemecek R, Ohkawa S, Świeboda-Sadlej A, Tjulandin SA, Van Cutsem E, Loberg R, Haddad V, Gansert JL, Bach BA, Carrato A.

Ann Oncol. 2015 May;26(5):921-7. doi: 10.1093/annonc/mdv027. Epub 2015 Jan 21.

12.

Regional variation and challenges in estimating the incidence of giant cell tumor of bone.

Liede A, Bach BA, Stryker S, Hernandez RK, Sobocki P, Bennett B, Wong SS.

J Bone Joint Surg Am. 2014 Dec 3;96(23):1999-2007. doi: 10.2106/JBJS.N.00367.

PMID:
25471915
13.

Failure of anti-EGFR therapy in p16-positive head and neck cancer - authors' reply.

Vermorken JB, Bach BA.

Lancet Oncol. 2013 Oct;14(11):e437-e438. doi: 10.1016/S1470-2045(13)70289-4. No abstract available.

PMID:
24079867
14.

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA; SPECTRUM investigators.

Lancet Oncol. 2013 Jul;14(8):697-710. doi: 10.1016/S1470-2045(13)70181-5. Epub 2013 Jun 6.

PMID:
23746666
15.

First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.

Demetri GD, Le Cesne A, Chawla SP, Brodowicz T, Maki RG, Bach BA, Smethurst DP, Bray S, Hei YJ, Blay JY.

Eur J Cancer. 2012 Mar;48(4):547-63. doi: 10.1016/j.ejca.2011.12.008. Epub 2012 Jan 11.

PMID:
22240283
16.

The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value.

Levacher M, Hulstaert F, Tallet S, Ullery S, Pocidalo JJ, Bach BA.

Clin Exp Immunol. 1992 Dec;90(3):376-82.

17.

Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection.

Kestens L, Vanham G, Gigase P, Young G, Hannet I, Vanlangendonck F, Hulstaert F, Bach BA.

AIDS. 1992 Aug;6(8):793-7.

PMID:
1418775
19.

Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry.

Loken MR, Brosnan JM, Bach BA, Ault KA.

Cytometry. 1990;11(4):453-9. Review.

20.
21.

Mechanisms of regulation of cell-mediated immunity: anti-I-A alloantisera interfere with induction and expression of T-cell-mediated immunity to cell-bound antigen in vivo.

Perry LL, Dorf ME, Bach BA, Benacerraf B, Greene MI.

Clin Immunol Immunopathol. 1980 Mar;15(3):279-92. No abstract available.

PMID:
6966196
22.

Idiotype-specific T cell immunity. I. Generation of effector and suppressor T lymphocytes reactive with myeloma idiotypic determinants.

Abbas AK, Perry LL, Bach BA, Greene MI.

J Immunol. 1980 Mar;124(3):1160-6. No abstract available.

PMID:
6153672
23.

Antigen- and receptor-driven regulatory mechanisms. II. Induction of suppressor T cells with idiotype-coupled syngeneic spleen cells.

Sy MS, Bach BA, Brown A, Nisonoff A, Benacerraf B, Greene MI.

J Exp Med. 1979 Nov 1;150(5):1229-40.

24.

Antigen- and receptor-driven regulatory mechanisms. I. Induction of suppressor T cells with anti-idiotypic antibodies.

Sy MS, Bach BA, Dohi Y, Nisonoff A, Benacerraf B, Greene MI.

J Exp Med. 1979 Nov 1;150(5):1216-28.

25.
28.
29.

C-reative protein in the rabbit: isolation, characterization and binding affinity to phosphocholine.

Bach BA, Gewurz H, Osmand AP.

Immunochemistry. 1977 Mar;14(3):215-9. No abstract available.

PMID:
863467

Supplemental Content

Support Center